Journal Logo

Letters

Breast Cancer Molecular Subtypes and Chemotherapy Schedules Used in Neoadjuvant or Adjuvant Setting May Show Different Effects in Nipple-Sparing Mastectomy

Altundag, Kadri M.D.

Author Information
Plastic and Reconstructive Surgery: September 2017 - Volume 140 - Issue 3 - p 495e
doi: 10.1097/PRS.0000000000003609
  • Free

Sir:

I want to congratulate Frey and colleagues on their article in which they explored the effects of neoadjuvant and adjuvant chemotherapy in nipple-sparing mastectomy.1 They found that nipple-sparing mastectomy is safe to perform in the setting of neoadjuvant and adjuvant chemotherapy. Furthermore, the authors reported that neoadjuvant (with or without adjuvant) chemotherapy increases the risk of complications.1 However, the authors did not provide detailed information about the chemotherapy (adjuvant chemotherapy versus adjuvant chemotherapy plus taxanes with or without trastuzumab) schedules, as neoadjuvant and adjuvant chemotherapy that patients receive may impact nipple-sparing mastectomy, and also I did not see any information about the effects of breast tumor subtypes (luminal A or B versus HER2-positive tumors versus triple-negative breast tumors) on nipple-sparing mastectomy. The medical literature did not provide any information about these two issues. If they report this information from patients’ charts, we might acquire new data about the association between tumor subtypes or chemotherapy schedules and nipple-sparing mastectomy.

DISCLOSURE

The author has no financial interest to declare in relation to the content of this communication.

Kadri Altundag, M.D.
MKA Breast Cancer Clinic
Tepe Prime, Cankaya
06800 Ankara, Turkey
[email protected]

REFERENCE

1. Frey JD, Choi M, Karp NS. The effect of neoadjuvant chemotherapy compared to adjuvant chemotherapy in healing after nipple-sparing mastectomy. Plast Reconstr Surg. 2017;139:10e19e.

GUIDELINES

Letters to the Editor, discussing material recently published in the Journal, are welcome. They will have the best chance of acceptance if they are received within 8 weeks of an article’s publication. Letters to the Editor may be published with a response from the authors of the article being discussed. Discussions beyond the initial letter and response will not be published. Letters submitted pertaining to published Discussions of articles will not be printed. Letters to the Editor are not usually peer reviewed, but the Journal may invite replies from the authors of the original publication. All Letters are published at the discretion of the Editor.

Letters submitted should pose a specific question that clarifies a point that either was not made in the article or was unclear, and therefore a response from the corresponding author of the article is requested.

Authors will be listed in the order in which they appear in the submission. Letters should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/.

We reserve the right to edit Letters to meet requirements of space and format. Any financial interests relevant to the content of the correspondence must be disclosed. Submission of a Letter constitutes permission for the American Society of Plastic Surgeons and its licensees and asignees to publish it in the Journal and in any other form or medium.

The views, opinions, and conclusions expressed in the Letters to the Editor represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.

The Journal requests that individuals submit no more than five (5) letters to Plastic and Reconstructive Surgery in a calendar year.

Copyright © 2017 by the American Society of Plastic Surgeons